ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc

Bullboard Posts

Post by Chainsawwon Dec 24, 2010 8:59am

216 Views

Post# 17892308

MARKET DEPTH

I cant post it here but i can tell you that there is about 85k offered at .43 and then it jumps to .48 with very little there until .50 with about 75k and after that its extremely thin. So next time that we go through these orders we may get a huge spike if it is accompanied with some good news. Insider buying confirms our suspicion that all is well and something good is coming. Hang in there

Bullboard Posts

Eminent acquires promising Nevada gold project